2018
Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine.
Garakani A. Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine. The Primary Care Companion For CNS Disorders 2018, 20 PMID: 30550646, DOI: 10.4088/pcc.18l02316.Peer-Reviewed Case Reports and Technical Notes
2012
Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal Of Affective Disorders 2012, 146: 262-265. PMID: 22840611, DOI: 10.1016/j.jad.2012.06.037.Peer-Reviewed Original Research
2010
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz J, Kolevzon A, Garakani A. The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances. Harvard Review Of Psychiatry 2010, 18: 266-278. PMID: 20825264, DOI: 10.3109/10673229.2010.507042.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntidepressive AgentsAntimanic AgentsAntipsychotic AgentsBipolar DisorderHumansLithium CompoundsConceptsBipolar disorderGold standardMajor treatment guidelinesFirst-line treatmentMainstay of treatmentUse of lamotrigineTreatment of maniaBipolar maintenanceAtypical antipsychoticsTreatment guidelinesBipolar depressionMaintenance treatmentPharmacological treatmentFDA indicationMEDLINE searchNew agentsPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists